KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Profit After Tax (2016 - 2025)

Historic Profit After Tax for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$130.6 million.

  • CRISPR Therapeutics AG's Profit After Tax fell 25006.57% to -$130.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$581.6 million, marking a year-over-year decrease of 5879.75%. This contributed to the annual value of -$581.6 million for FY2025, which is 5879.75% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Profit After Tax stood at -$130.6 million for Q4 2025, which was down 25006.57% from -$106.4 million recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year Profit After Tax high stood at $759.2 million for Q2 2021, and its period low was -$208.5 million during Q2 2025.
  • For the 5-year period, CRISPR Therapeutics AG's Profit After Tax averaged around -$68.7 million, with its median value being -$114.9 million (2021).
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Profit After Tax skyrocketed by 105312.97% in 2021, and later crashed by 25006.57% in 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Profit After Tax (Quarter) stood at -$141.2 million in 2021, then grew by 21.72% to -$110.6 million in 2022, then surged by 180.8% to $89.3 million in 2023, then crashed by 141.76% to -$37.3 million in 2024, then tumbled by 250.07% to -$130.6 million in 2025.
  • Its last three reported values are -$130.6 million in Q4 2025, -$106.4 million for Q3 2025, and -$208.5 million during Q2 2025.